Kristi Rosa

FLAME data show ctDNA-guided addition of chemotherapy to osimertinib improved PFS vs osimertinib alone in EGFR-mutant NSCLC.

Ahead of the 2026 ASCO Annual Meeting, results from the final analysis of the phase 3 KEYNOTE-522 study have been released.

The phase 3 HARMONi-6 showed an overall survival benefit with ivonescimab plus chemotherapy vs tislelizumab plus chemotherapy in squamous NSCLC.

Perioperative apalutamide plus ADT improved metastasis-free survival and pathologic responses in high-risk localized prostate cancer.

At the 2026 ASCO Annual Meeting, 3.5-year follow-up findings from the phase 3 EV-302/KEYNOTE-A39 study have been presented.

Adjuvant selpercatinib cut recurrence or death risk by 83% vs placebo in stage IB-IIIA RET fusion–positive NSCLC in LIBRETTO-432.

Results from the phase 3 MajesTEC-9 trial show superior PFS, OS, and ORR outcomes with teclistamab monotherapy in pretreated relapsed/refractory myeloma.

The phase 3 WU-KONG28 data showed that first-line sunvozertinib improved PFS and ORR vs chemotherapy in EGFR exon 20–mutant NSCLC.

Long-term follow-up from the RUBY trial showed few progression events and potential for curative intent in dMMR/MSI-H endometrial cancer.

At the 2026 ASCO Annual Meeting, results from the 7-year update of the phase 3 CROWN study were presented.

CHMP recommended trastuzumab deruxtecan for HER2-positive (IHC 3+) metastatic solid tumors, marking the first tumor-agnostic ADC opinion in the EU.

CHMP recommends camizestrant plus CDK4/6 inhibitor for ESR1-mutated HR+/HER2– advanced breast cancer, based on SERENA-6 phase 3 trial data.

Ahead of the 2026 ASCO Annual Meeting, results from the phase 3 FIGHT-302 study have been announced.

The FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.

Here is your cheat sheet to all oncology therapeutic options that were cleared or rejected by the FDA in April 2026.

The FDA has approved a once-daily, extended-release formulation of ruxolitinib for select myelofibrosis, polycythemia vera, and graft-vs-host disease.

Tisotumab vedotin plus carboplatin & pembrolizumab ± bevacizumab achieved 65.8% ORR and 28-month median OS in first-line recurrent/metastatic cervical cancer.

Trastuzumab pamirtecan achieved ~50% ORR in pretreated HER2-expressing endometrial cancer, earning FDA breakthrough designation per phase 1/2 trial data.

Relacorilant plus nab-paclitaxel cuts death risk by 35% and extends survival to 16 months in platinum-resistant ovarian cancer, per final ROSELLA trial data.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.

Gotistobart improved response rates and overall survival vs docetaxel in pretreated squamous NSCLC in stage 1 of the PRESERVE-003 trial.

Zongertinib showed strong systemic and intracranial responses in HER2-mutant NSCLC with a manageable safety profile in Beamion LUNG-1.

The FDA has cleared Pylarify TruVu injection, a new formulation of its F 18 PSMA imaging agent for prostate cancer.

KEYNOTE-B96 showed that pembrolizumab plus paclitaxel improved PFS and OS vs chemotherapy alone in platinum-resistant ovarian cancer.

In SunRISe-2, Gem-iDRS plus cetrelimab did not improve BI-EFS vs chemoradiotherapy in bladder-sparing MIBC and the trial stopped early for futility.

Disitamab vedotin elicited response rates over 50% in previously treated HER2-expressing advanced urothelial carcinoma.

In IMvigor011, adjuvant atezolizumab drove ctDNA clearance and improved DFS in ctDNA-positive muscle-invasive bladder cancer.

Short-course darolutamide boosted PSMA expression in some high-risk localized prostate cancer, supporting improved PSMA PET imaging strategies.

Obrixtamig plus platinum chemo showed a 72% response rate and manageable safety in frontline DLL3-positive NEC in the phase 1 DAREON-7 trial.

Real-world data show liso-cel drives high responses in relapsed/refractory CLL, with an 85% ORR, a 44% CR rate, and manageable safety.